Alma Gómez

Dr. Alma Gómez

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2015 in Journal of Applied Phycology
Verified
Journal Article
Closed access
PDF file
AGAlma Gómez
Alma Gómez
JBJorge Benavides
Jorge Benavides
Marco Rito-PalomaresMarco Rito-Palomares
Marco Rito-Palomares

15 January 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AVAugusto Vazquez-Rodriguez
Augusto Vazquez-Rodriguez
XVXimena G Vasto-Anzaldo
Ximena G Vasto-Anzaldo
DPDaniel Barboza Perez
Daniel Barboza Perez
EVEduardo Vázquez-Garza
Eduardo Vázquez-Garza
HCHéctor Chapoy-Villanueva
Héctor Chapoy-Villanueva
JMJosé Ruben Morones-Ramírez
José Ruben Morones-Ramírez
Bacterial species are able to colonize and establish communities in biotic and abiotic surfaces. Moreover, within the past five decades, incidence of bacterial strains resistant to currently used antibiotics has increased dramatically. This has led to diverse health issues and economical losses for different industries. Therefore, there is a latent need to develop new and more efficient antimicrobials. This work reports an increased production of an exopolysaccharide in a native yeast strain isolated from the Mexican Northeast, Rhodotorula mucilaginosa UANL-001L, when co-cultured with E. coli. The exopolysaccharide produced is chemically and physically characterized and its applications as an antimicrobial and antibiofilm are explored. The exopolysaccharide is capable of inhibiting planktonic growth and biofilm formation in Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus. Additionally, the exopolysaccharide studied here does not exhibit cytotoxic effects when assessed both, in vitro against an H9c2 mammalian cell line, and in vivo in a murine toxicity model. Taken together, the properties of this exopolysaccharide indicate that it has potential applications to inhibit bacterial colonization in medical and industrial settlings.

15 August 2014 in Journal of Chemical Technology & Biotechnology
Verified
Journal Article
Closed access
PDF file
AGAlma Gómez
Alma Gómez
JBJorge Benavides
Jorge Benavides
Marco Rito-PalomaresMarco Rito-Palomares
Marco Rito-Palomares


31 October 2017 in Journal of Chemical Technology & Biotechnology
Verified
Journal Article
Closed access
PDF file
AGAlma Gómez
Alma Gómez
JGJosé González-Valdez
José González-Valdez
MGMirna Alejandra Alejandra González González
Mirna Alejandra Alejandra González González
JBJorge Benavides
Jorge Benavides
Marco Rito-PalomaresMarco Rito-Palomares
Marco Rito-Palomares

28 January 2024 in Microorganisms
Verified
Journal Article
Open access
PDF file
JGJessica J. Gomez-Lugo
Jessica J. Gomez-Lugo
Nestor Casillas-VegaNestor Casillas-Vega
Nestor Casillas-Vega
AGAlma Gómez
Alma Gómez
IBIsaías Balderas-Rentería
Isaías Balderas-Rentería
Xristo ZarateXristo Zarate
Xristo Zarate
(1) Background: Producing active antimicrobial peptides with disulfide bonds in bacterial strains is challenging. The cytoplasm of Escherichia coli has a reducing environment, which is not favorable to the formation of disulfide bonds. Additionally, E. coli may express proteins as insoluble aggregates known as inclusion bodies and have proteolytic systems that can degrade recombinant peptides. Using E. coli strains like SHuffle and tagging the peptides with fusion proteins is a common strategy to overcome these difficulties. Still, the larger size of carrier proteins can affect the final yield of recombinant peptides. Therefore, a small fusion protein that can be purified using affinity chromatography may be an ideal strategy for producing antimicrobial peptides in E. coli. (2) Methods: In this study, we investigated the use of the small metal-binding protein SmbP as a fusion partner for expressing and purifying the antimicrobial peptide scygonadin in E. coli. Two constructs were designed: a monomer and a tandem repeat; both were tagged with SmbP at the N-terminus. The constructs were expressed in E. coli SHuffle T7 and purified using immobilized metal-affinity chromatography. Finally, their antimicrobial activity was determined against Staphylococcus aureus. (3) Results: SmbP is a remarkable fusion partner for purifying both scygonadin constructs, yielding around 20 mg for the monomer and 30 mg for the tandem repeat per 1 mL of IMAC column, reaching 95% purity. Both protein constructs demonstrated antimicrobial activity against S. aureus at MICs of 4 μM and 40 μM, respectively. (4) Conclusions: This study demonstrates the potential of SmbP for producing active peptides for therapeutic applications. The two scygonadin constructs in this work showed promising antimicrobial activity against S. aureus, suggesting they could be potential candidates for developing new antimicrobial drugs.